论文部分内容阅读
目的探讨程序性死亡配体-1(PD-L1)在人非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法采用Western blot和免疫组织化学染色法检测41例NSCLC患者的肺癌组织、癌旁组织、正常肺组织和15例肺部良性病变患者的正常肺组织中的PD-L1表达,分析NSCLC患者PD-L1表达的影响因素。结果 NSCLC患者肺癌组织中PD-L1阳性表达率为80.49%(33/41),肺良性病变患者正常肺组织中几乎无PD-L1表达。NSCLC患者肺癌组织中PD-L1表达高于癌旁组织及正常肺组织(P<0.05)。PD-L1的表达与肿瘤患者分期、淋巴结转移和远处转移相关(P<0.05),而与肿瘤病理分型、患者年龄、性别、吸烟史及肿瘤大小等无关(P>0.05)。结论 PD-L1在NSCLC组织中显著高表达,在NSCLC进展中发挥重要作用,可能成为NSCLC预后的判断指标及免疫治疗的新靶点。
Objective To investigate the expression and clinical significance of PD-L1 in human non-small cell lung cancer (NSCLC). Methods Western blot and immunohistochemical staining were used to detect the expression of PD-L1 in normal lung tissue from 41 cases of NSCLC patients with lung cancer, adjacent normal lung tissue and 15 cases of benign lung disease. The expression of PD- The influencing factors of L1 expression. Results The positive rate of PD-L1 in NSCLC patients was 80.49% (33/41). There was almost no PD-L1 expression in normal lung tissues of patients with benign lung diseases. The expression of PD-L1 in NSCLC patients was significantly higher than that in adjacent non-cancerous tissues and normal lung tissues (P <0.05). The expression of PD-L1 was correlated with tumor stage, lymph node metastasis and distant metastasis (P <0.05), but not with tumor pathological type, age, sex, smoking history and tumor size (P> 0.05). Conclusions PD-L1 is highly expressed in NSCLC tissues and plays an important role in the progression of NSCLC. It may be a new prognostic indicator of NSCLC and a new target of immunotherapy.